Catalog No.S1952 Synonyms: Xanthotoxin, NCI-C55903
Molecular Weight(MW): 216.19
Methoxsalen is a naturally occurring photoactive substance found in the seeds of the Ammi majus (Umbelliferae) plant, used in the diagnosis and treatment of psoriasis; A CYP2A5/6 inhibitor.
Purity & Quality Control
Choose Selective P450 (e.g. CYP17) Inhibitors
|Description||Methoxsalen is a naturally occurring photoactive substance found in the seeds of the Ammi majus (Umbelliferae) plant, used in the diagnosis and treatment of psoriasis; A CYP2A5/6 inhibitor.|
Methoxsalen inhibits CYP2A6 (Ki = 0.8 μM) with about 3.5- 94-fold greater potency than other P450s, except for CYP1A2 (Ki = 0.2 μM). Methoxsalen shows noncompetitive inhibition of nicotine metabolism, with an apparent Ki value of 0.1 μM in cDNA-expressing microsomes.  Methoxsalen is metabolized in human liver microsomes at the rate of 50-100 pmol/mg protein/min (approx. 30% of the activity in mouse liver microsomes). Methoxsalen is a very potent inhibitor of human cytochrome P450 2A6 (CYP2A6) and mouse Cyp2a-5-mediated coumarin 7-hydroxylation in vitro. 
|In vivo||Methoxsalen results in a significant decrease in the following factors: number and diameter of corpus lutei, Graafian follicles, diameter of granulosa cell layer and oocytes, number of primordial and primary and growing follicles, while the number of atretic follicle is increased. Methoxsalen also significantly reduces circulating estrogen levels in blood serum of oogenesis Balb/C mice.  Methoxsalen dose-dependently stimulates a sustained increase in short-circuit current in the mouse jejunum. Methoxsalen increases the open probability of the basolateral IK(Ca) channel of isolated crypts in the mouse jejunum.  Methoxsalen effectively reverses trimethyltin (TMT)-induced memory impairment on both Y-maze and passive avoidance tests in mice. Methoxsalen inhibits brain AchE activity. Methoxsalen significantly ameliorates the level of oxidative stress. |
-  Zhang W, et al. Drug Metab Dispos,?001, 29(6), 897-902.
-  Mäenpää J, et al. Biochem Pharmacol, 1994, 48(7), 1363-1369.
-  Farhadi M, et al. Cell J,?014, 15(4), 348-355.
|In vitro||DMSO||43 mg/mL (198.89 mM)|
|Ethanol||5 mg/mL (23.12 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03563040||Not yet recruiting||Lymphoma T-Cell Cutaneous|Mycosis Fungoides/Sezary Syndrome||European Organisation for Research and Treatment of Cancer - EORTC|Mallinckrodt||December 1 2018||Phase 2|
|NCT03605940||Not yet recruiting||Acute-graft-versus-host Disease||Central Hospital Nancy France||October 1 2018||Phase 2|
|NCT03512756||Recruiting||Pancreatic Cancer||Tyme Inc||March 27 2018||Phase 2|
|NCT02524847||Recruiting||Steroid Refractory Acute Graft Versus Host Disease||Mallinckrodt||January 20 2016||Phase 3|
|NCT02181257||Active not recruiting||Bronchiolitis Obliterans Syndrome (BOS)||Washington University School of Medicine|Centers for Medicare and Medicaid Services|Mallinckrodt||January 2015||--|
|NCT02322190||Suspended||Chronic Graft vs. Host Disease|Graft vs Host Disease|Graft-Versus-Host Disease||National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)||December 20 2014||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.